In addition, other outcomes were significantly impacted in the KL NSCLC group, as these patients exhibited a shorter progression-free (p < 0.001) and overall (p = 0.0015) survival compared to those of the KRAS mutant/STK wild-type patients [13]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.